Galecto, Inc. announced it has completed enrollment in Parts II and III of its ongoing 3-part Phase Ib/IIa trial of GB1211, GULLIVER-2, in liver cirrhosis.
[Galecto, Inc.]
Sorry, but the selected Zotpress account can't be found.
Home Newsletters Hepatic Cell News Galecto Completes Enrollment in Phase Ib/IIa GULLIVER-2 Trial of Its Selective, Oral...
